231 related articles for article (PubMed ID: 32943063)
1. Utility of the EULAR Sjögren syndrome disease activity index in Japanese children: a retrospective multicenter cohort study.
Iwata N; Tomiita M; Kobayashi I; Inoue Y; Nonaka Y; Okamoto N; Umebayashi H; Hara R; Ito Y; Sato Y; Mori M
Pediatr Rheumatol Online J; 2020 Sep; 18(1):73. PubMed ID: 32943063
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of systemic activity of pediatric primary Sjögren's syndrome by EULAR Sjögren's syndrome disease activity index (ESSDAI).
Kobayashi I; Okura Y; Ueki M; Tozawa Y; Takezaki S; Yamada M; Ariga T
Mod Rheumatol; 2019 Jan; 29(1):130-133. PubMed ID: 29529894
[TBL] [Abstract][Full Text] [Related]
3. Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial.
Cornec D; Devauchelle-Pensec V; Mariette X; Jousse-Joulin S; Berthelot JM; Perdriger A; Puéchal X; Le Guern V; Sibilia J; Gottenberg JE; Chiche L; Hachulla E; Yves Hatron P; Goeb V; Hayem G; Morel J; Zarnitsky C; Dubost JJ; Saliou P; Pers JO; Seror R; Saraux A
Arthritis Care Res (Hoboken); 2017 Apr; 69(4):528-535. PubMed ID: 27390310
[TBL] [Abstract][Full Text] [Related]
4. ESSDAI activity index of the SJÖGRENSER cohort: analysis and comparison with other European cohorts.
Rosas J; Sánchez-Piedra C; Fernández-Castro M; Andreu JL; Martínez-Taboada V; Olivé A;
Rheumatol Int; 2019 Jun; 39(6):991-999. PubMed ID: 30891620
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
Bowman SJ; Fox R; Dörner T; Mariette X; Papas A; Grader-Beck T; Fisher BA; Barcelos F; De Vita S; Schulze-Koops H; Moots RJ; Junge G; Woznicki JN; Sopala MA; Luo WL; Hueber W
Lancet; 2022 Jan; 399(10320):161-171. PubMed ID: 34861168
[TBL] [Abstract][Full Text] [Related]
6. Articular and Peripheral Nervous System Involvement Are Linked to the Long-Term Outcome in Primary Sjögren's Syndrome: The Relevance of Single Organ Manifestations Rather Than a Composite Score as Predictors.
Quartuccio L; Gandolfo S; Zabotti A; Zandonella Callegher S; Fabro C; De Vita S
Front Immunol; 2019; 10():1527. PubMed ID: 31354708
[No Abstract] [Full Text] [Related]
7. Association between systemic activity ındex and dry eye severity in patients with primary Sjögren syndrome.
Ozek D; Kemer OE; Omma A
Arq Bras Oftalmol; 2019; 82(1):45-50. PubMed ID: 30403265
[TBL] [Abstract][Full Text] [Related]
8. Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI).
Seror R; Theander E; Brun JG; Ramos-Casals M; Valim V; Dörner T; Bootsma H; Tzioufas A; Solans-Laqué R; Mandl T; Gottenberg JE; Hachulla E; Sivils KL; Ng WF; Fauchais AL; Bombardieri S; Valesini G; Bartoloni E; Saraux A; Tomsic M; Sumida T; Nishiyama S; Caporali R; Kruize AA; Vollenweider C; Ravaud P; Vitali C; Mariette X; Bowman SJ;
Ann Rheum Dis; 2015 May; 74(5):859-66. PubMed ID: 24442883
[TBL] [Abstract][Full Text] [Related]
9. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.
Meiners PM; Arends S; Brouwer E; Spijkervet FK; Vissink A; Bootsma H
Ann Rheum Dis; 2012 Aug; 71(8):1297-302. PubMed ID: 22258489
[TBL] [Abstract][Full Text] [Related]
10. Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: examination of data from the UK Primary Sjögren's Syndrome Registry.
Dumusc A; Ng WF; James K; Griffiths B; Price E; Pease C; Emery P; Lanyon P; Jones A; Bombardieri M; Sutcliffe N; Pitzalis C; Gupta M; McLaren J; Cooper A; Giles I; Isenberg D; Saravanan V; Coady D; Dasgupta B; McHugh N; Young-Min S; Moots R; Gendi N; Akil M; Barone F; Fisher B; Rauz S; Richards A; Bowman S
Swiss Med Wkly; 2018; 148():w14588. PubMed ID: 29442344
[TBL] [Abstract][Full Text] [Related]
11. Do the EULAR Sjögren's syndrome outcome measures correlate with health status in primary Sjögren's syndrome?
Lendrem D; Mitchell S; McMeekin P; Gompels L; Hackett K; Bowman S; Price E; Pease CT; Emery P; Andrews J; Lanyon P; Hunter J; Gupta M; Bombardieri M; Sutcliffe N; Pitzalis C; McLaren J; Cooper A; Regan M; Giles I; Isenberg D; Saravanan V; Coady D; Dasgupta B; McHugh N; Young-Min S; Moots R; Gendi N; Akil M; Griffiths B; Ng WF;
Rheumatology (Oxford); 2015 Apr; 54(4):655-9. PubMed ID: 25240612
[TBL] [Abstract][Full Text] [Related]
12. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI).
Seror R; Bootsma H; Saraux A; Bowman SJ; Theander E; Brun JG; Baron G; Le Guern V; Devauchelle-Pensec V; Ramos-Casals M; Valim V; Dörner T; Tzioufas A; Gottenberg JE; Solans Laqué R; Mandl T; Hachulla E; Sivils KL; Ng WF; Fauchais AL; Bombardieri S; Priori R; Bartoloni E; Goeb V; Praprotnik S; Sumida T; Nishiyama S; Caporali R; Kruize AA; Vollenweider C; Ravaud P; Meiners P; Brito-Zerón P; Vitali C; Mariette X;
Ann Rheum Dis; 2016 Feb; 75(2):382-9. PubMed ID: 25480887
[TBL] [Abstract][Full Text] [Related]
13. European League Against Rheumatism Sjögren's Syndrome Disease Activity Index and European League Against Rheumatism Sjögren's Syndrome Patient-Reported Index: a complete picture of primary Sjögren's syndrome patients.
Seror R; Gottenberg JE; Devauchelle-Pensec V; Dubost JJ; Le Guern V; Hayem G; Fauchais AL; Goeb V; Hachulla E; Hatron PY; Larroche C; Morel J; Pedriger A; Puechal X; Rist S; Saraux A; Sene D; Sibilia J; Vittecoq O; Zarnitsky C; Labetoulle M; Ravaud P; Mariette X
Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1358-64. PubMed ID: 23436737
[TBL] [Abstract][Full Text] [Related]
14. Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjögren's syndrome.
Brito-Zerón P; Acar-Denizli N; Ng WF; Horváth IF; Rasmussen A; Seror R; Li X; Baldini C; Gottenberg JE; Danda D; Quartuccio L; Priori R; Hernandez-Molina G; Armagan B; Kruize AA; Kwok SK; Kvarnstrom M; Praprotnik S; Sene D; Gerli R; Solans R; Rischmueller M; Mandl T; Suzuki Y; Isenberg D; Valim V; Wiland P; Nordmark G; Fraile G; Bootsma H; Nakamura H; Giacomelli R; Devauchelle-Pensec V; Hofauer B; Bombardieri M; Trevisani VFM; Hammenfors D; Pasoto SG; Retamozo S; Gheita TA; Atzeni F; Morel J; Vollenweider C; Zeher M; Sivils K; Xu B; Bombardieri S; Sandhya P; De Vita S; Minniti A; Sánchez-Guerrero J; Kilic L; van der Heijden E; Park SH; Wahren-Herlenius M; Mariette X; Ramos-Casals M;
Rheumatology (Oxford); 2020 Sep; 59(9):2350-2359. PubMed ID: 31873754
[TBL] [Abstract][Full Text] [Related]
15. Disease activity and damage in patients with primary Sjogren's syndrome: Prognostic value of salivary gland ultrasonography.
Milic V; Colic J; Cirkovic A; Stanojlovic S; Damjanov N
PLoS One; 2019; 14(12):e0226498. PubMed ID: 31891590
[TBL] [Abstract][Full Text] [Related]
16. Development and Application of the Placebo Response Model in Clinical Trials for Primary Sjögren's Syndrome.
Wang ZZ; Zheng QS; Liu HX; Li LJ
Front Immunol; 2021; 12():783246. PubMed ID: 34868062
[TBL] [Abstract][Full Text] [Related]
17. Baseline disease activity influences subsequent achievement of patient acceptable symptom state in Sjögren's syndrome.
Park EH; Ha YJ; Kang EH; Song YW; Scofield RH; Lee YJ
Rheumatology (Oxford); 2021 Jun; 60(6):2714-2724. PubMed ID: 33188390
[TBL] [Abstract][Full Text] [Related]
18. Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study).
Meiners PM; Vissink A; Kroese FG; Spijkervet FK; Smitt-Kamminga NS; Abdulahad WH; Bulthuis-Kuiper J; Brouwer E; Arends S; Bootsma H
Ann Rheum Dis; 2014 Jul; 73(7):1393-6. PubMed ID: 24473674
[TBL] [Abstract][Full Text] [Related]
19. Systemic manifestations of primary Sjögren's syndrome out of the ESSDAI classification: prevalence and clinical relevance in a large international, multi-ethnic cohort of patients.
Retamozo S; Acar-Denizli N; Rasmussen A; Horváth IF; Baldini C; Priori R; Sandhya P; Hernandez-Molina G; Armagan B; Praprotnik S; Kvarnstrom M; Gerli R; Sebastian A; Solans R; Rischmueller M; Pasoto SG; Valim V; Nordmark G; Kruize A; Nakamura H; Hofauer B; Giacomelli R; Fernandes Moça Trevisani V; Devauchelle-Pensec V; Atzeni F; Gheita TA; Consani-Fernández S; Szántó A; Sivils K; Gattamelata A; Danda D; Kilic L; Bartoloni E; Bombardieri S; Sánchez-Guerrero J; Wahren-Herlenius M; Mariette X; Ramos-Casals M; Brito-Zerón P;
Clin Exp Rheumatol; 2019; 37 Suppl 118(3):97-106. PubMed ID: 31464664
[TBL] [Abstract][Full Text] [Related]
20. A phase II investigator-initiated pilot study with low-dose cyclosporine A for the treatment of articular involvement in primary Sjögren's syndrome.
Kedor C; Zernicke J; Hagemann A; Gamboa LM; Callhoff J; Burmester GR; Feist E
Clin Rheumatol; 2016 Sep; 35(9):2203-10. PubMed ID: 27470087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]